SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs > Inovio Pharmaceuticals, Inc. (INO)

Genetic Testing for Cancer

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
hlegweakreturns Member Profile
Followed By 1
Posts 448
Boards Moderated 0
Alias Born 07/31/13
160x600 placeholder
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 2/14/2017 6:20:00 PM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 2/14/2017 6:08:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/13/2017 2:17:02 PM
Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater ... "GlobeNewswire Inc." - 2/13/2017 6:00:00 AM
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences "GlobeNewswire Inc." - 1/30/2017 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/25/2017 2:46:26 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/4/2017 3:54:04 PM
Inovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study "GlobeNewswire Inc." - 12/21/2016 8:00:00 AM
Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute "GlobeNewswire Inc." - 12/6/2016 8:00:00 AM
Inovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Aga... "GlobeNewswire Inc." - 12/1/2016 9:00:00 AM
Inovio Applies to Cease Reporting to Canadian Securities Regulatory Authorities; NASDAQ Listing and US Reporting Unaffected "GlobeNewswire Inc." - 11/25/2016 8:00:00 AM
Inovio’s Co-Founder and Chair of its Scientific Advisory Board Selected as a Top 20 Translational Researcher "GlobeNewswire Inc." - 11/21/2016 8:00:00 AM
Inovio Wins Deloitte’s “Fast 500” Growth Award "GlobeNewswire Inc." - 11/16/2016 8:00:00 AM
Inovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients... "GlobeNewswire Inc." - 11/14/2016 7:00:00 AM
Inovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death "GlobeNewswire Inc." - 11/10/2016 10:00:00 AM
Inovio Pharmaceuticals Reports 2016 Third Quarter Financial Results "GlobeNewswire Inc." - 11/9/2016 7:30:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/9/2016 6:03:55 AM
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences "GlobeNewswire Inc." - 11/4/2016 8:00:00 AM
Inovio Pharmaceuticals to Report Third Quarter 2016 Financial Results November 9, 2016 "GlobeNewswire Inc." - 10/26/2016 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/24/2016 9:01:46 AM
Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed "GlobeNewswire Inc." - 10/24/2016 8:00:00 AM
Inovio CEO Selected As 2016 Healthcare Innovator "GlobeNewswire Inc." - 10/21/2016 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/14/2016 4:04:51 PM
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio "GlobeNewswire Inc." - 10/12/2016 8:00:00 AM
Inovio’s Zika Vaccine Selected As 2016 Technology Breakthrough "GlobeNewswire Inc." - 9/12/2016 8:00:00 AM
hlegweakreturns   Friday, 10/18/13 06:04:49 AM
Re: None
Post # of 13809 
Genetic Testing for Cancer
Is evolving very quickly and many folks are getting into the business. And there is more than one in New Jersey. Roche is entering this market, and they are not alone. Yesterday Bloomberg had an article on Quest entering the Breast-Cancer Test Market that is currently dominated by Myriad. I don't think Roche has any interest in Quest, but they obviously are looking for expanding their genetic diagnostic capability going forward, as evidenced by the PACB deal, and another agreement with a smaller, and interesting player in this market. So here is the article if you have any interest in tangential developments:

"Quest Diagnostics Inc. (DGX), the biggest U.S. operator of medical labs, began yesterday to sell a test for two breast cancer genes, providing competition for Myriad Genetics Inc. and potentially helping to reduce costs for women fearful they are at risk of the disease.Quest will sell the most comprehensive version of its test for the BRCA1 and BRCA2 genes for $2,500, said Richard Bender, a consultant for the Madison, New Jersey-based company. The price compares with almost $3,400 that Medicare pays for the most comprehensive version of a test from Myriad.

Myriad held a U.S. monopoly over the BRCA tests until June, when the U.S. Supreme Court invalidated parts of its gene patents. Immediately afterward, Ambry Genetics Corp. and another closely held company said they were entering the BRCA market. Quest is the largest competitor to move into the field. Quest’s test “will certainly be comparable to if not better than the data provided by Myriad” in its ability to identify a harmful mutation, Bender said by telephone.
Quest’s incursion into the BRCA testing market sets up a potential legal battle with Myriad, which has various remaining patents on its tests. “We feel we offer a test that is the gold standard in quality,” Ronald Rogers, a Myriad spokesman, said in a phone interview."

Quest’s test “does not violate any valid BRCA patent that Myriad Genetics may assert,” Wendy Bost, a Quest spokeswoman, said in an e-mail.
Quest said in an Oct. 10 complaint filed in federal court in Santa Ana, California, that it believes Myriad will bring a patent-infringement lawsuit if it starts selling its BRCA test products.
Myriad hasn’t yet been served with Quest’s complaint, said Rogers. “Once we receive that, we will read through it and weigh our options,” he said.
The case is Quest Diagnostics Inc. v. Myriad Genetics Inc. (MYGN), 13-cv-01587, U.S. District Court, Central District of California (Santa Ana).

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist